These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 33186337

  • 1. Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
    Dobkin A, McWalters J, Barnett R, Ray LL, Espinoza L, McGinn AP, Atrio JM, Keller MJ.
    Sex Transm Dis; 2020 Dec; 47(12):819-824. PubMed ID: 33186337
    [Abstract] [Full Text] [Related]

  • 2. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [Abstract] [Full Text] [Related]

  • 3. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
    Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke MA, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo N, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC.
    Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
    [Abstract] [Full Text] [Related]

  • 4. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
    Baum MM, Butkyavichene I, Churchman SA, Lopez G, Miller CS, Smith TJ, Moss JA.
    Int J Pharm; 2015 Nov 10; 495(1):579-587. PubMed ID: 26386138
    [Abstract] [Full Text] [Related]

  • 5. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.
    AIDS; 2016 Mar 13; 30(5):743-51. PubMed ID: 26605514
    [Abstract] [Full Text] [Related]

  • 6. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM, Rosen RK, Vargas SE, Getz ML, Dawson L, Guillen M, Ramirez JJ, Baum MM, Vincent KL.
    PLoS One; 2018 Mar 13; 13(5):e0197269. PubMed ID: 29758049
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City.
    Watnick D, Keller MJ, Stein K, Bauman LJ.
    AIDS Behav; 2018 Feb 13; 22(2):421-436. PubMed ID: 29147810
    [Abstract] [Full Text] [Related]

  • 9. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
    Moss JA, Butkyavichene I, Churchman SA, Gunawardana M, Fanter R, Miller CS, Yang F, Easley JT, Marzinke MA, Hendrix CW, Smith TJ, Baum MM.
    Antimicrob Agents Chemother; 2016 Jun 13; 60(6):3759-66. PubMed ID: 27067321
    [Abstract] [Full Text] [Related]

  • 10. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
    Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF.
    Proc Natl Acad Sci U S A; 2013 Oct 01; 110(40):16145-50. PubMed ID: 24043812
    [Abstract] [Full Text] [Related]

  • 11. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X, Nwokolo N, Korologou-Linden R, Hill A, Whitlock G, Day-Weber I, McClure MO, Boffito M.
    HIV Med; 2018 Jan 01; 19(1):1-6. PubMed ID: 28657199
    [Abstract] [Full Text] [Related]

  • 12. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK, Baeten JM.
    Expert Opin Drug Saf; 2016 Jan 01; 15(2):265-73. PubMed ID: 26634852
    [Abstract] [Full Text] [Related]

  • 13. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM, ANRS IPERGAY study group.
    Lancet HIV; 2020 Feb 01; 7(2):e113-e120. PubMed ID: 31784343
    [Abstract] [Full Text] [Related]

  • 14. Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    Stoner MCD, Browne EN, Gundacker HM, Hawley I, Chen BA, Hoesley C, Scheckter R, Piper J, Singh D, Song M, Liu A, van der Straten A.
    PLoS One; 2022 Feb 01; 17(2):e0263664. PubMed ID: 35192655
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
    Mofenson LM, Baggaley RC, Mameletzis I.
    AIDS; 2017 Jan 14; 31(2):213-232. PubMed ID: 27831952
    [Abstract] [Full Text] [Related]

  • 17. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
    Thurman AR, Schwartz JL, Ravel J, Gajer P, Marzinke MA, Yousefieh N, Anderson SM, Doncel GF.
    PLoS One; 2019 Jan 14; 14(5):e0217229. PubMed ID: 31107913
    [Abstract] [Full Text] [Related]

  • 18. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
    Bunge KE, Dezzutti CS, Hendrix CW, Marzinke MA, Spiegel HML, Moncla BJ, Schwartz JL, Meyn LA, Richardson-Harman N, Rohan LC, Hillier SL.
    J Int AIDS Soc; 2018 Aug 14; 21(8):e25156. PubMed ID: 30101439
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L, ANRS IPERGAY Study Group.
    Lancet HIV; 2017 Sep 14; 4(9):e402-e410. PubMed ID: 28747274
    [Abstract] [Full Text] [Related]

  • 20. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
    Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM, Magure T, Nakabiito C, Marrazzo JM, Chirenje ZM, Riddler SA, MTN-003B Protocol Team.
    J Acquir Immune Defic Syndr; 2016 Mar 01; 71(3):287-94. PubMed ID: 26866954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.